VINU GANTI: Open Payments
NPI 1760499826 · GERMANTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,996 in 98 payments from 20 companies in 2025. Trend: 2023 $3,033 · 2024 $2,406 · 2025 $1,996
Food & beverage: $1,876Education: $120
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $263 |
| AstraZeneca Pharmaceuticals LP | 12 | $253 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $218 |
| ABBVIE INC. | 14 | $215 |
| Lilly USA, LLC | 8 | $168 |
| GlaxoSmithKline, LLC. | 7 | $154 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Amgen Inc. | 5 | $93 |
| Merck Sharp & Dohme LLC | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
Products named: Kerendia, BREZTRI, TRELEGY ELLIPTA, QULIPTA, OPSUMIT, VRAYLAR, Ozempic, KISUNLA.
Industry payments across MD — which companies pay providers there.
